Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Getting to MRD in ALL boosted survival

Hay KA. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7005.

Key clinical point: Minimal residual disease (MRD)–negative complete remission was strongly associated with improved survival outcomes.

Major finding: Patients who achieved MRD-negative complete remission had an improved median disease-free survival at 7.6 months versus 0.8 months (P less than .0001)

Study details: A retrospective analysis including 53 patients with ALL who had bone marrow or extramedullary disease at baseline and had received CD19 CAR T cells at or under the maximum tolerated dose at least 1 year prior to this analysis.

Disclosures: Researchers reported financial ties to Juno Therapeutics, Cell Medica, Celgene, Eureka Therapeutics, Genentech/Roche, Gilead Sciences, Kite Pharma, Novartis, and others.

Source: Hay KA. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7005.

Read the article.

Citation:

Hay KA. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7005.

This Week's Must Reads

Improved myeloma outcomes associated with having prescription drug coverage, Olszewski A et al. J Clin Oncol. 2018 Aug 16. doi: 10.1200/JCO.2018.77.8894

For lymphoma patients, insurance is a matter of life or death , Goldstein JS et al. Blood. 2018 Jul 24. doi: 10.1182/blood-2018-03-839035

Expansion in clinical trial eligibility requested by ASCO, Friends of Cancer and ASCO letter to the FDA

Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

Must Reads in ALL (Acute Lymphoblastic Leukemia)

ALL patients are not routinely getting appropriate IT MTX , Sommerfeld SA et al. EHA Congress, Abstract PS930.

ALL patients' liver toxicities linked to antibiotics, other therapies, Minetto P et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PS934.

Patient-specific risk factors for BCC, SCC examined in study, Scott J et al. Presentation at American College of Mohs Surgery, May 2018.

Getting to MRD in ALL boosted survival, Hay KA. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7005.

Pediatric cancers rising, Siegel DA et al. ASPHO 2018, Abstract 605.